HIV/AIDS Clinical Trials

Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults

Condition: HIV Infections

NCT ID: NCT00111605

Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults

Condition: HIV Infections

NCT ID: NCT00115960

Antigenic Competition in HIV Preventive Vaccines

Condition: HIV Infections

NCT ID: NCT01159990

Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults

Condition: HIV Seronegativity; HIV Preventive Vaccine

NCT ID: NCT01418235

Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein

Condition: HIV Infections

NCT ID: NCT00529698

Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults

Condition: HIV Infections

NCT ID: NCT00820846

Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults

Condition: HIV Infections

NCT ID: NCT00141024

A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials

Condition: HIV Infections

NCT ID: NCT00029913

Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials

Condition: HIV Infection; HIV Seronegativity

NCT ID: NCT00789789

Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers

Condition: HIV Infections

NCT ID: NCT00545987

A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)

Condition: HIV Infection

NCT ID: NCT01441193

A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers

Condition: HIV Infections; HIV Seronegativity

NCT ID: NCT00000868

HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults

Condition: HIV Infections; HIV Seronegativity

NCT ID: NCT00013572

Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women

Condition: HIV Infections; HIV Seronegativity

NCT ID: NCT00000809

Withdrawn

A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers

Condition: HIV Infections; HIV Seronegativity

NCT ID: NCT00000774

Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults

Condition: HIV Infections; HIV Seronegativity

NCT ID: NCT00027261

Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected Mothers

Condition: HIV-1; HIV Infections

NCT ID: NCT00981695

Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)

Condition: HIV Infections; Pregnancy; HIV Seronegativity

NCT ID: NCT00001046

Withdrawn

A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers

Condition: HIV Infections; HIV Seronegativity

NCT ID: NCT00000879

Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1/2-uninfected Mothers

Condition: HIV-1; HIV Infections

NCT ID: NCT00982579

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

Condition: HIV Infections; HIV Seronegativity

NCT ID: NCT00001043

A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine

Condition: HIV Infections; HIV Seronegativity

NCT ID: NCT00001136

A Study to Test the Safety of Three Experimental HIV Vaccines

Condition: HIV Infections; HIV Seronegativity

NCT ID: NCT00000946

Phase 1 Safety Study of Two Experimental HIV Vaccines

Condition: AIDS Vaccines; HIV Infections; HIV-1

NCT ID: NCT00479999

Screening Protocol for HIV Vaccine Studies

Condition: HIV Seronegativity; HIV Infections

NCT ID: NCT00031304

ALVAC-HIV vCP1452 Alone and Combined With MN rgp120

Condition: HIV Infections; HIV Seronegativity

NCT ID: NCT00011037

Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)

Condition: HIV Infections; Pregnancy; HIV Seronegativity

NCT ID: NCT00000777

Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm

Condition: HIV Infections; HIV Seronegativity

NCT ID: NCT00076817

Analysis of Immune Responses to HIV Vaccines

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT00068978

Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults

Condition: HIV Infections

NCT ID: NCT00083603

A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59

Condition: HIV Infections; HIV Seronegativity

NCT ID: NCT00000972

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers

Condition: HIV Infections

NCT ID: NCT00001072

Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults

Condition: HIV Infections

NCT ID: NCT00124007

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers

Condition: HIV Infections

NCT ID: NCT00000847

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules

Condition: HIV Infections

NCT ID: NCT00001076

A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)

Condition: HIV Infections

NCT ID: NCT00001020

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

Condition: HIV Infections

NCT ID: NCT00000846

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults

Condition: HIV Infections

NCT ID: NCT00001096

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

Condition: HIV Infections

NCT ID: NCT00865566

Recruiting(En español)

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults

Condition: HIV Infections

NCT ID: NCT00001052

A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers

Condition: HIV Infections

NCT ID: NCT00000871

Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults

Condition: HIV Infections

NCT ID: NCT00054860

Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults

Condition: HIV Infections

NCT ID: NCT00301184

Safety of and Immune Response to an HIV-1 Vaccine (ALVAC-HIV vCP1521) in Infants Born to HIV Infected Mothers

Condition: HIV Infections

NCT ID: NCT00098163

Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults

Condition: HIV Infections

NCT ID: NCT00413725

Suspended(En español)

Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults

Condition: HIV Infections

NCT ID: NCT00415649

Withdrawn(En español)

Safety of and Immune Response to a DNA HIV Vaccine Followed By an Adenoviral Vector HIV Vaccine in Healthy Adults

Condition: HIV Infections

NCT ID: NCT00125970

Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa

Condition: HIV Infections

NCT ID: NCT00498056

Withdrawn(En español)

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

Condition: HIV Infections

NCT ID: NCT00384787

Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults

Condition: HIV Infections

NCT ID: NCT00123968

Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults

Condition: HIV Infections

NCT ID: NCT00000904

Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in Uganda

Condition: HIV Infections

NCT ID: NCT00007423

A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects

Condition: HIV Infections

NCT ID: NCT00001053

A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects

Condition: HIV Infections

NCT ID: NCT00000795

A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects

Condition: HIV Infections

NCT ID: NCT00000798

Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP

Condition: HIV Infections

NCT ID: NCT00076037

A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines

Condition: HIV Infections

NCT ID: NCT00076063

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers

Condition: HIV Infections

NCT ID: NCT00001055

Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa

Condition: HIV Infections

NCT ID: NCT00063778

A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers

Condition: HIV Infections

NCT ID: NCT00000884

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers

Condition: HIV Infections

NCT ID: NCT00000813

Safety of an HIV DNA Vaccine Given to HIV Uninfected Adults

Condition: HIV Infections

NCT ID: NCT00043511

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines

Condition: HIV Infections

NCT ID: NCT00000746

A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers

Condition: HIV Infections

NCT ID: NCT00000832

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals

Condition: HIV Infections

NCT ID: NCT00001026

A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects

Condition: HIV Infections

NCT ID: NCT00000845

Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals

Condition: HIV Infections

NCT ID: NCT00955006

Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults

Condition: HIV Infections

NCT ID: NCT00097838

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults

Condition: HIV Infections

NCT ID: NCT00000853

A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART

Condition: HIV Infection

NCT ID: NCT01571466

A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults

Condition: HIV Infections

NCT ID: NCT00001031

Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults

Condition: HIV Infections

NCT ID: NCT01095224

A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)

Condition: HIV Infections

NCT ID: NCT00001021

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

Condition: HIV Infections

NCT ID: NCT00001042

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.

Condition: HIV Infections

NCT ID: NCT00001044

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.

Condition: HIV Infections

NCT ID: NCT00000866

Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults

Condition: HIV Infections

NCT ID: NCT00071851

Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults

Condition: HIV Infections

NCT ID: NCT01103687

Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052

Condition: HIV Infections

NCT ID: NCT00091416

Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults

Condition: HIV Infections

NCT ID: NCT00472719

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers

Condition: HIV Infections

NCT ID: NCT00001090

A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers

Condition: HIV Infections

NCT ID: NCT00001088

Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

Condition: HIV Infection

NCT ID: NCT00252148

Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults

Condition: HIV Infections

NCT ID: NCT00119873

Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

Condition: HIV Infections

NCT ID: NCT01260727

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules

Condition: HIV Infections

NCT ID: NCT00000957

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose

Condition: HIV Infections

NCT ID: NCT00001056

A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

Condition: HIV Infections

NCT ID: NCT00001037

Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults

Condition: HIV Infections

NCT ID: NCT00695877

Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers

Condition: HIV Infections

NCT ID: NCT00062530

Not yet recruiting

Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults

Condition: HIV Infections

NCT ID: NCT00061243

Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults

Condition: HIV Infections

NCT ID: NCT00073216

Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins

Condition: HIV Infections

NCT ID: NCT01054872

Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults

Condition: HIV Infections

NCT ID: NCT00574600

Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults

Condition: HIV Infections

NCT ID: NCT00486408

Suspended(En español)

Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

Condition: HIV Infections

NCT ID: NCT00801697

Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults

Condition: HIV Infections

NCT ID: NCT00428337

Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection

Condition: HIV Infections

NCT ID: NCT00386633

An Investigational Combination Vaccine Given to People Who Are Not Infected With HIV

Condition: HIV Infections

NCT ID: NCT00027365

A Study to Prepare for Future HIV Vaccine Studies

Condition: HIV Infections

NCT ID: NCT00029744

Candidate HIV Vaccine

Condition: HIV Infections

NCT ID: NCT00089531

Safety of the EnvPro HIV Vaccine in Healthy Volunteers

Condition: HIV Infections

NCT ID: NCT00076947

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

Condition: HIV Infections

NCT ID: NCT00000956

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

Condition: HIV Infections

NCT ID: NCT00000757

Development of a New HIV Vaccine

Condition: HIV Infections

NCT ID: NCT00051922

A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)

Condition: HIV Infections

NCT ID: NCT00000775

A Phase I Study of Modified Vaccinia Virus Ankara (MVA-B) in Healthy Volunteers at Low Risk of HIV Infection

Condition: HIV Infections

NCT ID: NCT00679497

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)

Condition: HIV Infections

NCT ID: NCT00000968

A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

Condition: HIV Infections

NCT ID: NCT00000745

A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)

Condition: HIV Infections

NCT ID: NCT00000886

Evaluation of the Safety of and Immune Response to an HIV Vaccine in Healthy Adults

Condition: HIV Infections

NCT ID: NCT00051454

Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)

Condition: HIV Infections

NCT ID: NCT00000630

A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine LFn-p24 Administered by the Intramuscular (IM) Route in Healthy Adults

Condition: HIV Infections

NCT ID: NCT00412477

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)

Condition: HIV Infections

NCT ID: NCT00000767

Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults

Condition: HIV Infections

NCT ID: NCT00991354

Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults

Condition: HIV Infections

NCT ID: NCT00069030

A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)

Condition: HIV Infections

NCT ID: NCT00000631

Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV

Condition: HIV Infections; H1N1 Influenza

NCT ID: NCT01002040

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 Mcg of Env 2-3 in MF59

Condition: HIV Infections; HIV Seronegativity

NCT ID: NCT00000632

A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus

Condition: HIV Infections

NCT ID: NCT00000683

Evaluate Tolerability of a Multi-envelope, Prime-boost HIV Vaccine in Healthy Adults

Condition: HIV Infections

NCT ID: NCT00623753

Terminated

Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant

Condition: HIV Infections

NCT ID: NCT00001019

Determining an Effective Site (Groin Versus Arm) for Giving HIV Vaccines

Condition: HIV Infections

NCT ID: NCT00056745

Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers

Condition: HIV Infections

NCT ID: NCT00490074

HIV-1 Vaccine Test in Uninfected Adult Volunteers

Condition: Healthy; HIV Seronegativity

NCT ID: NCT00009685

The Effectiveness of Human Antibodies in Influencing an AIDS-Like Disease in Monkeys

Condition: HIV Infections

NCT ID: NCT00031109

Early Immune Responses to Vaccination - A Substudy to HVTN 205

Condition: HIV Infections

NCT ID: NCT00908323

Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults

Condition: HIV Infections

NCT ID: NCT00528489

Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B

Condition: HIV Infections

NCT ID: NCT00007332

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months

Condition: HIV Infections

NCT ID: NCT00000749

Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial

Condition: HIV-1

NCT ID: NCT00337181

Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines

Condition: HIV Infections

NCT ID: NCT01264445

Screening HIV-Infected Patients for Vaccine Studies

Condition: HIV Infection

NCT ID: NCT00051519

HIV-1 Vaccine Test in Uninfected Adult Volunteers

Condition: Healthy

NCT ID: NCT00045838

Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid

Condition: Human Immunodeficiency Virus Infections; HIV Infections

NCT ID: NCT00888446

A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers

Condition: HIV; HIV Infections

NCT ID: NCT00851383

A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)

Condition: HIV-1; HIV Infections

NCT ID: NCT00849680

Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT00850616

A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)(COMPLETED)

Condition: HIV-1; HIV Infections

NCT ID: NCT00849732

DCVax Plus Poly ICLC in Healthy Volunteers

Condition: HIV-1 Infection; HIV Infection; Healthy Volunteers

NCT ID: NCT01127464

Preventative Misconception Intervention

Condition: HIV; HIV Infections

NCT ID: NCT01049139

Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

Condition: HIV Infections

NCT ID: NCT00376090

Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults

Condition: HIV Infections

NCT ID: NCT00618605

Safety of and Immune Response to Prime/Boost Vaccine Regimens in Healthy, HIV-1 Uninfected, Ad5 Seronegative Adults

Condition: HIV Infections

NCT ID: NCT00961883

Observational Study of the Preventive Trial With HIV-1 Tat Protein

Condition: Healthy Subjects

NCT ID: NCT01024764

Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant

Condition: HIV Infection

NCT ID: NCT01473810